Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 20Gastrointestinal 14Genitourinary 8CNS 8Sarcoma 7Dermatologic 7Breast 7Thoracic 5Head & Neck 4Other solid neoplasm 2Lymphoid 1

Conditions

Solid Tumors That Overexpress HER2 (HER2 Positive) 1Cervical Adenocarcinoma 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Immunoglobulin G × Other solid neoplasm × Clear all
NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

NCT02286219 2017-09-18

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)

Bristol-Myers Squibb

Phase 1 Completed
30 enrolled
Other solid neoplasm

Solid Tumors That Overexpress HER2 (HER2 Positive)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡